Investigadores
Inicio
Investigadores
Hospital Clinic. Hospital Sant Joan de Déu. Banc de Sang i Teixits (IDIBAPS). Barcelona.
Terapia Génica
Inmunoterapia Celular (células CAR)
Desarrollos Tecnológicos y Terapéuticos
Manel Juan Otero
Investigador principal
Grupo de Investigación: Hospital Clinic. Hospital Sant Joan de Déu. Banc de Sang i Teixits (IDIBAPS). Barcelona.
ANNA ALONSO SALADRIGUES
Investigador colaborador
Grupo de Investigación: Hospital Clinic. Hospital Sant Joan de Déu. Banc de Sang i Teixits (IDIBAPS). Barcelona.
Carlos Fernández de Larrea Rodríguez
Investigador colaborador
Grupo de Investigación: Hospital Clinic. Hospital Sant Joan de Déu. Banc de Sang i Teixits (IDIBAPS). Barcelona.
Julio Delgado González
Investigador colaborador
Grupo de Investigación: Hospital Clinic. Hospital Sant Joan de Déu. Banc de Sang i Teixits (IDIBAPS). Barcelona.
Maria Castella Castella
Investigador colaborador
Grupo de Investigación: Hospital Clinic. Hospital Sant Joan de Déu. Banc de Sang i Teixits (IDIBAPS). Barcelona.
Marta Español Rego
Investigador colaborador
Grupo de Investigación: Hospital Clinic. Hospital Sant Joan de Déu. Banc de Sang i Teixits (IDIBAPS). Barcelona.
Miquel Lozano Molero
Investigador colaborador
Grupo de Investigación: Hospital Clinic. Hospital Sant Joan de Déu. Banc de Sang i Teixits (IDIBAPS). Barcelona.
Susana Rives Solà
Investigador colaborador
Grupo de Investigación: Hospital Clinic. Hospital Sant Joan de Déu. Banc de Sang i Teixits (IDIBAPS). Barcelona.
Valentín Ortiz-Maldonado Gibson
Investigador colaborador
Grupo de Investigación: Hospital Clinic. Hospital Sant Joan de Déu. Banc de Sang i Teixits (IDIBAPS). Barcelona.
Gómez-Puerta J.A., Monegal A., Ponce A., Peris P., Martínez-Cibrian N., Sarmiento-Monroy J.C., Ortiz-Maldonado V., Triguero A., Fernández de Larrea C., Delgado J., García-Herrera A., Albero-González R., Bosch-Amate X., Español-Rego M., González A., Sanmartí R., Juan M.. Rheumatologic complications of CAR-T Cell therapy. Experience of a single center. Seminars in Arthritis and Rheumatism. April 2025. DOI: 10.1016/j.semarthrit.2024.152610.
Impacto: 4.6. Cuartil: Q1
El Maimouni C., Daca-Alvarez M., Delgado J., Pellisé M., Balaguer F.. Venetoclax as a possible chemopreventive agent in adenomatous polyposis: A case report. Gastroenterologia y Hepatologia. March 2025. DOI: 10.1016/j.gastrohep.2024.502239.
Impacto: 2.2. Cuartil: Q3
Zugasti I., Tormo-Ratera M., Oliver-Caldés A., Soler-Perromat J.C., González-Calle V., Moreno D.F., Cabañas V., López-Muñoz N., Bartolomé-Solanas Á., Español-Rego M., Reguera-Ortega J.L., Rosiñol L., López-Corral L., Tovar N., Rodríguez-Lobato L.G., Alvarez Perez R.M., Varea S., Olesti E., Gomez-Grande A., Frutos L., Tamayo P., Juan M., Moraleda J.M., Urbano-Ispizua Á., González-Navarro E.A., Martínez-López J., Mateos M.V., Tomás X., Setoain X., Fernández de Larrea C.. Clinical impact of [<sup>18</sup>F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood Advances. 11 February 2025. DOI: 10.1182/bloodadvances.2024014360.
Impacto: 7.4. Cuartil: Q1
Liang E.C., Huang J.J., Portuguese A.J., Ortiz-Maldonado V., Albittar A., Wuliji N., Basom R., Jeon Y., Wu Q., Torkelson A., Kirchmeier D., Chutnik A., Pender B., Sorror M., Hill J.A., Kopmar N.E., Banerjee R., Cowan A.J., Green D., Gopal A.K., Poh C., Shadman M., Hirayama A.V., Till B.G., Kimble E.L., Iovino L., Chapuis A.G., Otegbeye F., Cassaday R.D., Milano F., Turtle C.J., Maloney D.G., Gauthier J.. Development and validation of predictive models of early immune effector cell–associated hematotoxicity. Blood Advances. 11 February 2025. DOI: 10.1182/bloodadvances.2024014455.
Impacto: 7.4. Cuartil: Q1
Besliu C., Tanase A.D., Rotaru I., Espinoza J., Vidal L., Poelman M., Juan M., de Larrea C.F., Saini K.S.. The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies. Cancers. February 2025. DOI: 10.3390/cancers17030525.
Impacto: 4.5. Cuartil: Q1
Albarrán-Fernández V., Angelats L., Delgado J., Gros A., Urbano-Ispizua Á., Guedan S., Prat A.. Unlocking the potential of engineered immune cell therapy for solid tumors. Nature communications. 29 January 2025. DOI: 10.1038/s41467-025-56527-0.
Impacto: 14.7. Cuartil: Q1
(1er decil)
Bachiller M., Barceló-Genestar N., Rodriguez-Garcia A., Alserawan L., Dobaño-López C., Giménez-Alejandre M., Castellsagué J., Colell S., Otero-Mateo M., Antoñana-Vildosola A., Español-Rego M., Ferruz N., Pascal M., Martín-Antonio B., Anguela X.M., Fillat C., Olesti E., Calvo G., Juan M., Delgado J., Pérez-Galán P., Urbano-Ispizua Á., Guedan S.. ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma. Molecular Therapy. 8 January 2025. DOI: 10.1016/j.ymthe.2024.11.028.
Impacto: 12.1. Cuartil: Q1
(1er decil)
Garcia-Guiñon A., Charry P.A., Jimenez M., Sarra J., Delgado I., Segura de la Torre L., Santaliestra M., Garcia-Pintos M., Gonzalez Y., Senin A., Motlló C., Abella E., Cabezudo E., Granell M., Sancho E., Herranz M.J., Seres Y., Gironella M., Soler J.A., Marti-Tutusaus J.M., Ben Azaiz R., Fernandez de Larrea C.. Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma. Annals of Hematology. 2025. DOI: 10.1007/s00277-025-06240-1.
Impacto: 3.0. Cuartil: Q2
Medina Á., Muntañola A., Crespo M., Ramírez Á., Hernández-Rivas J.Á., Abrisqueta P., Alcoceba M., Delgado J., de la Serna J., Espinet B., González M., Loscertales J., Serrano A., Terol M.J., Yáñez L., Bosch F.. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC). Medicina Clinica. 2025. DOI: 10.1016/j.medcli.2024.10.018.
Impacto: 2.6. Cuartil: Q1
Ollé J., Larque A.B., de Larrea C.F., Diekmann F., Cucchiari D.. Searching for the minimum required dose of daratumumab to induce effective plasma cell depletion in antibody-mediated rejection of the kidney graft: a case report. Journal of Nephrology. 2025. DOI: 10.1007/s40620-024-02182-5.
Impacto: 2.7. Cuartil: Q2
Arguello-Tomas M., Mozas P., Albiol N., López-Esteban M., Sierra J., Nomdedéu J., Martinez-Laperche C., Moga E., Piñeyroa J.A., Delgado J., Osorio S., Moreno C.. Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy. Cancer. 1 January 2025. DOI: 10.1002/cncr.35552.
Impacto: 6.1. Cuartil: Q1
Sanchez-Sierra N., Alonso-Saladrigues A., Perez-Jaume S., Rivera-Perez C., Faura A., Arques L., Isola I.M., Torrebadell M., Diaz J.L.D., Rives S.. Platelet Counts Prior to Lymphodepletion Chemotherapy are Associated with Clinical Outcome in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After CAR-T19-Cell Therapy. Pediatric Blood and Cancer. 2025. DOI: 10.1002/pbc.31604.
Impacto: 2.4. Cuartil: Q1
Merz M., Albici A.M., von Tresckow B., Rathje K., Fenk R., Holderried T., Müller F., Tovar N., Oliver-Cáldes A., Vucinic V., Kharboutli S., Bärmann B.N., Ayuk F., Platzbecker U., Stölzel F., Schub N., Schmitz F., Fandrei D., Born P., Khandanpour C., Hanoun C., Hörster K., Teichert M., Jeker B., Hoffmann M., Kröger N., de Larrea C.F., Pabst T., Gagelmann N.. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study. HemaSphere. January 2025. DOI: 10.1002/hem3.70070.
Impacto: 7.6. Cuartil: Q1
Theron A., Alonso-Saladrigues A., Dapena J.L., López-Duarte M., Diaz de Heredia C., Verdú-Amorós J., Sarrate E., Esperanza-Cebollada E., Cuatrecasas E., Andreu S., Conde N., Sanchez-Sierra N., Isola I., Camós M., Torrebadell M., Rives S., Català A.. Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children. British Journal of Haematology. January 2025. DOI: 10.1111/bjh.19862.
Impacto: 5.1. Cuartil: Q1
Zabaleta A., Puig N., Cedena M.T., Oliver-Caldes A., Perez J.J., Moreno C., Tamariz-Amador L.E., Rodriguez-Otero P., Prosper F., Gonzalez-Calle V., López-Corral L., Rey-Búa B., Puertas B., Mirás F., Sánchez-Pina J.M., López-Muñoz N., Juan M., González-Navarro E.A., Urbano Á., de Larrea C.F., Blade J., Lahuerta J.J., Martinez-Lopez J., Mateos M.V., San Miguel J.F., Paiva B.. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy. American Journal of Hematology. January 2025. DOI: 10.1002/ajh.27526.
Impacto: 10.1. Cuartil: Q1
(1er decil)
Ullrich F., Bröckelmann P.J., Turki A.T., Khan A.M., Chiru E.D., Vetter M., Tresckow B.V., Wirth R., Cordoba R., Ortiz-Maldonado V., Fülöp T., Neuendorff N.R.. Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma. Journal for ImmunoTherapy of Cancer. 2 December 2024. DOI: 10.1136/jitc-2024-009462.
Impacto: 10.3. Cuartil: Q1
(1er decil)
Merz M., Dima D., Hashmi H., Ahmed N., Stölzel F., Holderried T.A.W., Fenk R., Müller F., Tovar N., Oliver-Cáldes A., Rathje K., Davis J.A., Fandrei D., Vucinic V., Kharboutli S., Baermann B.N., Ayuk F., Platzbecker U., Albici A.M., Schub N., Schmitz F., Shune L., Khouri J., Anwer F., Raza S., McGuirk J., Mahmoudjafari Z., Green K., Khandanpour C., Teichert M., Jeker B., Hoffmann M., Kröger N., von Tresckow B., de Larrea C.F., Pabst T., Abdallah A.O., Gagelmann N.. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. Blood Cancer Journal. December 2024. DOI: 10.1038/s41408-024-01197-2.
Impacto: 12.9. Cuartil: Q1
(1er decil)
Martinez-Verbo L., Veselinova Y., Llinàs-Arias P., García-Prieto C.A., Noguera-Castells A., Pato M.L., Bueno-Costa A., Campillo-Marcos I., Villanueva L., Oliver-Caldes A., Cardus O., Salsench S.V., García-Ortiz A., Valeri A., Rojas E.A., Barrena N., Gutiérrez N.C., Prósper F., Agirre X., Fernández de Larrea C., Martínez-López J., Ferrer G., Esteller M.. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma. Leukemia. December 2024. DOI: 10.1038/s41375-024-02419-z.
Impacto: 12.8. Cuartil: Q1
(1er decil)
Cibeira M.T., Rodríguez-Lobato L.G., Alejaldre A., Fernández de Larrea C.. Neurological manifestations of MGUS. Hematology. American Society of Hematology. Education Program. 25 November 2024. DOI: 10.1182/hematology.2024000665.
Impacto: 2.9. Cuartil: Q1
Guerrero-Murillo M., Rill-Hinarejos A., Trincado J.L., Bataller A., Ortiz-Maldonado V., Benítez-Ribas D., Español-Rego M., González-Navarro E.A., Martínez-Cibrián N., Marchese D., Martín-Martín L., Martín García-Sancho A., Rives S., Heyn H., Juan M., Urbano-Ispizúa Á., Delgado J., Orfao A., Mereu E., Bueno C., Menendez P.. Integrative single-cell multi-omics of CD19-CAR<sup>pos</sup> and CAR<sup>neg</sup> T cells suggest drivers of immunotherapy response in B cell neoplasias. Cell Reports Medicine. 19 November 2024. DOI: 10.1016/j.xcrm.2024.101803.
Impacto: 11.7. Cuartil: Q1
(1er decil)
Moreno D.F., Jiménez C., Escalante F., Askari E., Castellanos-Alonso M., Arnao M., Heredia Á., Canales M., Alcalá M., Bermúdez A., Saus Carreres A., Casanova M., Palomera L., Motlló C., García-Sánchez R., Ríos Rull P., García-Sanz R., Fernández de Larrea C.. Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry. HemaSphere. November 2024. DOI: 10.1002/hem3.70029.
Impacto: 7.6. Cuartil: Q1
Piñeyroa J.A., López-Oreja I., Nadeu F., Martínez-Farran A., Aróstegui J.I., López-Guerra M., Correa J.G., Fabregat A., Villamor N., Monge-Escatín I., Albiol N., Costa D., Aymerich M., Beà S., Campo E., Delgado J., Colomer D., Mozas P.. Association of Genomic Alterations with the Presence of Serum Monoclonal Proteins in Chronic Lymphocytic Leukemia. Cells. November 2024. DOI: 10.3390/cells13221839.
Impacto: 5.1. Cuartil: Q2
Ortiz de Landazuri I., Oliver-Caldés A., Español-Rego M., Agulló C., Contreras M.T., Zabaleta A., Puig N., Cabañas V., González-Calle V., Zugasti I., Inogés S., Rodríguez Otero P., Martin-Antonio B., Reguera J.L., López-Diaz de Cerio A., Aróstegui J.I., Uribe-Herranz M., Benítez-Ribas D., Rodríguez-Lobato L.G., González E.A., Tovar N., Charry P., Navarro S., Rosiñol L., Tréboles K., Mora G., Yagüe J., Moraleda J.M., Urbano-Ispizua Á., Mateos M.V., Pascal M., Paiva B., Juan M., Fernández de Larrea C.. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells. British Journal of Haematology. October 2024. DOI: 10.1111/bjh.19589.
Impacto: 5.1. Cuartil: Q1
Bailén R., Iacoboni G., Delgado J., López-Corral L., Hernani-Morales R., Ortiz-Maldonado V., Guerreiro M., Caballero A.C., Guerra-Domínguez M.L., Sánchez-Pina J.M., Peña M., Torrent A., Pérez-Martínez A., Bastos-Oreiro M., Reguera-Ortega J.L., Martín A., Hernandez-Boluda J.C., Martínez-Cibrián N., Sanz J., Briones J., Henriquez H.L., Calbacho M., Mussetti A., Sancho J.M., Barba P., Kwon M.. Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO. Transplantation and Cellular Therapy. October 2024. DOI: 10.1016/j.jtct.2024.06.022.
Impacto: 3.6. Cuartil: Q1
Pennesi E., Brivio E., Ammerlaan A.C.J., Jiang Y., van der Velden V.H.J., Beverloo H.B., Sleight B., Locatelli F., Brethon B., Rossig C., Engstler G., Nilsson A., Bruno B., Petit A., Bielorai B., Rizzari C., Rialland F., Rubio-San-Simón A., Bautista Sirvent F.J., Diaz-De-Heredia C., Rives S., Zwaan C.M.. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22<sup>+</sup> acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial. Haematologica. October 2024. DOI: 10.3324/haematol.2023.284409.
Impacto: 8.2. Cuartil: Q1
Lozano E., Mena M.P., Garrabou G., Cardús O., Díaz T., Moreno D.F., Mañé-Pujol J., Oliver-Caldés A., Battram A., Tovar N., Cibeira M.T., Rodríguez-Lobato L.G., Bladé J., de Larrea C.F., Rosiñol L.. Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma. Clinical Cancer Research. 1 September 2024. DOI: 10.1158/1078-0432.CCR-24-0117.
Impacto: 10.0. Cuartil: Q1
Skerget S., Penaherrera D., Chari A., Jagannath S., Siegel D.S., Vij R., Orloff G., Jakubowiak A., Niesvizky R., Liles D., Berdeja J., Levy M., Wolf J., Usmani S.Z., Steis R., Srinivas S., Roy V., Rodríguez P., Oriol A., Kumar S., Krsnik I., Matkiwsky M., Girnius S., Conde M., Chandra S., Anderson R., Solomon W., Richards D., Patel D., Menter A., Kaya H., Hsu G., Hassoun H., Bargay J., Anderson L., Abella E., Yalamachili M., Wachsman W., Volterra F., Onitilo A., Min F., Shieh M., Bar M., Ngaiza J., Harris W., Sebag M., Robles R., Yost K., Grossbard M., Lewis D.Q., Kambhampati S., Costello C., Chinea A., Silva C., Balaraman R., Martinez-Chamorro C., Granell M., Azaceta G., Fonseca R., Kuzma C., Klein L., de Larrea C.F., Dodlapati J., Shao S., Graham M., Harroff A., Milner C., Chu M., Lunning M., Silbermann R., Mannem S., Sampol A., Rios P., Paganini J.V., Bahlis N., Dakhil S., Trudel S., Hernández M., Gasparetto C., Ascensao J., Zonder J., Benson D., Meehan K., Rifkin R., Christofferson A.W., Nasser S., Aldrich J.L., Legendre C., Benard B., Miller C., Turner B., Kurdoglu A., Washington M., Yellapantula V., Adkins J.R., Cuyugan L., Boateng M., Helland A., Kyman S., McDonald J.. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nature Genetics. September 2024. DOI: 10.1038/s41588-024-01853-0.
Impacto: 31.7. Cuartil: Q1
(1er decil)
Juan-Ribelles A., Bautista F., Cañete A., Rubio-San-Simón A., Alonso-Saladrigues A., Hladun R., Rives S., Dapena J.L., Fernández J.M., Lassaletta Á., Cruz O., Ramírez-Villar G., Fuster J.L., de Heredia C.D., García-Ariza M., Quiroga E., del Mar Andrés M., Verdú-Amorós J., Molinés A., Herrero B., López M., Márquez C., Toboso M., Lendínez F., Sirvent J.G., Tallón M., Rodríguez G., Acha T., Moreno L., Fernández-Teijeiro A.. ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer. Clinical and Translational Oncology. September 2024. DOI: 10.1007/s12094-024-03445-0.
Impacto: 2.8. Cuartil: Q2
Mingot-Castellano M.E., Reguera-Ortega J.L., Zafra Torres D., Hernani R., Lopez-Godino O., Guerreiro M., Herrero B., López-Corral L., Luna A., Gonzalez-Pinedo L., Chinea-Rodriguez A., Africa-Martín A., Bailen R., Martinez-Cibrian N., Balsalobre P., Filaferro S., Alonso-Saladrigues A., Barba P., Perez-Martinez A., Calbacho M., Perez-Simón J.A., Sánchez-Pina J.M.. Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients. Journal of Clinical Medicine. September 2024. DOI: 10.3390/jcm13175117.
Impacto: 3.0. Cuartil: Q1
Cabrera-Maqueda J.M., Sepulveda M., García R.R., Muñoz-Sánchez G., Martínez-Cibrian N., Ortíz-Maldonado V., Lorca-Arce D., Guasp M., Llufriu S., Martinez-Hernandez E., Armangue T., Fonseca E.G., Alba-Isasi M.T., Delgado J., Dalmau J., Juan M., Saiz A., Blanco Y.. CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year. Neurology: Neuroimmunology and NeuroInflammation. 6 August 2024. DOI: 10.1212/NXI.0000000000200292.
Impacto: 7.8. Cuartil: Q1
(1er decil)
Gómez-Puerta J.A., Ponce A., Triguero A., de Larrea C.F., Sanmartí R.. Transient palindromic rheumatism induced by chimeric antigen receptor T-cell therapy. Rheumatology (United Kingdom). 1 August 2024. DOI: 10.1093/rheumatology/keae046.
Impacto: 4.7. Cuartil: Q1
Lin Y., Qiu L., Usmani S., Joo C.W., Costa L., Derman B., Du J., Einsele H., Fernandez de Larrea C., Hajek R., Ho P.J., Kastritis E., Martinez-Lopez J., Mateos M.V., Mikhael J., Moreau P., Nagarajan C., Nooka A., O'Dwyer M., Schjesvold F., Sidana S., van de Donk N.W., Weisel K., Zweegman S., Raje N., Otero P.R., Anderson L.D., Kumar S., Martin T.. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. The Lancet Oncology. August 2024. DOI: 10.1016/S1470-2045(24)00094-9.
Impacto: 41.6. Cuartil: Q1
(1er decil)
Delgado J., Juan M., Calvo G., Urbano-Ispizua Á.. The development of academic CAR T cells. The Lancet Haematology. July 2024. DOI: 10.1016/S2352-3026(24)00170-4.
Impacto: 15.4. Cuartil: Q1
(1er decil)
Abrisqueta P., González-Barca E., Ferrà C., Ríos-Herranz E., Fernández de la Mata M., Delgado J., Andreu R., Hernández-Rivas J.Á., Terol M.J., Navarro A., Vidriales M.B., Baltasar P., De la Serna J., Ramírez Á., Ballester C., Moreno C., García-Marco J.A., Córdoba R., Yáñez L., Casado L.F., González M., Bosch F.. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC). eClinicalMedicine. July 2024. DOI: 10.1016/j.eclinm.2024.102642.
Impacto: 9.6. Cuartil: Q1
(1er decil)
Martín García-Sancho A., Presa M., Pardo C., Martín-Escudero V., Oyagüez I., Ortiz-Maldonado V.. Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain. Cancers. July 2024. DOI: 10.3390/cancers16132301.
Impacto: 4.5. Cuartil: Q1
Alegre A., Gironella M., Escalante F., Bergua J.M., Martínez-Chamorro C., López A., González E., Bárez A., Somolinos N., Persona E.P., Cabrera A.S., Soler A., Rodríguez B.I., López J.M., González Y., Giménez V.C., Sampol A., Muñoz C., Vilanova D., Durán M., Fernández de Larrea C.. Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting. HemaSphere. July 2024. DOI: 10.1002/hem3.81.
Impacto: 7.6. Cuartil: Q1
Peyrony O., Garcia-Pouton N., Chumbita M., Teijon-Lumbreras C., Aiello T.F., Monzó-Gallo P., Gallardo-Pizarro A., Ortiz-Maldonado V., Martinez-Cibrian N., Delgado J., de Larrea C.F., Mensa J., Puerta-Alcalde P., Soriano A., Garcia-Vidal C.. Chimeric Antigen Receptor T-Cell Postinfusion Fever: Infection Profile, Clinical Parameters, and Biomarkers Trends to Assist Antibiotic Stewardship. Open Forum Infectious Diseases. 1 July 2024. DOI: 10.1093/ofid/ofae398.
Impacto: 3.8. Cuartil: Q2
Wu J.H., Pennesi E., Bautista F., Garrett M., Fukuhara K., Brivio E., Ammerlaan A.C.J., Locatelli F., van der Sluis I.M., Rossig C., Chen-Santel C., Bielorai B., Petit A., Starý J., Díaz-de-Heredia C., Rives S., O’Marcaigh A., Rizzari C., Engstler G., Nysom K., Rubio-San-Simón A., Bruno B., Bertrand Y., Brethon B., Rialland F., Plat G., Dirksen U., Sramkova L., Zwaan C.M., Huitema A.D.R.. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059. Clinical Pharmacokinetics. July 2024. DOI: 10.1007/s40262-024-01386-z.
Impacto: 4.6. Cuartil: Q1
Delgado J.. InsT-ALLing CD7 chimeric antigen receptors before transplantation. British Journal of Haematology. June 2024. DOI: 10.1111/bjh.19498.
Impacto: 5.1. Cuartil: Q1
Oliver-Caldes A., Español-Rego M., Zabaleta A., González-Calle V., Navarro-Velázquez S., Inogés S., López-Díaz de Cerio A., Cabañas V., López-Muñoz N., Rodríguez-Otero P., Reguera J.L., Moreno D.F., Martínez-Cibrian N., López-Corral L., Pérez-Amill L., Martin-Antonio B., Rosiñol L., Cid J., Tovar N., Sáez-Peñataro J., López-Parra M., Olesti E., Guillén E., Varea S., Rodríguez-Lobato L.G., Battram A.M., González M.S., Sánchez-Salinas A., González-Navarro A., Ortiz-Maldonado V., Delgado J., Prósper F., Juan M., Martínez-López J., Moraleda J.M., Mateos M.V., Urbano-Ispizua Á., Paiva B., Pascal M., de Larrea C.F.. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clinical Cancer Research. 15 May 2024. DOI: 10.1158/1078-0432.CCR-23-3759.
Impacto: 10.0. Cuartil: Q1
Gagelmann N., Dima D., Merz M., Hashmi H., Ahmed N., Tovar N., Oliver-Caldés A., Stölzel F., Rathje K., Fischer L., Born P., Schäfer L., Albici A.M., Schub N., Kfir-Erenfeld S., Assayag M., Asherie N., Wulf G.G., Kharboutli S., Müller F., Shune L., Davis J.A., Anwer F., Vucinic V., Platzbecker U., Ayuk F., Kröger N., Khouri J., Gurnari C., McGuirk J., Stepensky P., Abdallah A.O., Fernández De Larrea C.. Development and Validation of a Prediction Model of Outcome after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology. 10 May 2024. DOI: 10.1200/JCO.23.02232.
Impacto: 42.1. Cuartil: Q1
(1er decil)
de Daniel A., Rodríguez-Lobato L.G., Tovar N., Cibeira M.T., Moreno D.F., Oliver-Caldés A., Isola I., Lozano E., Bladé J., Rosiñol L., Fernández de Larrea C.. The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma. HemaSphere. May 2024. DOI: 10.1002/hem3.76.
Impacto: 7.6. Cuartil: Q1
Delgado J.. CAR therapy: The role of academic institutions in its production. Bulletin de l'Academie Nationale de Medecine. May 2024. DOI: 10.1016/j.banm.2024.01.019.
Impacto: 0.3. Cuartil: Q3
Brillembourg H., Martínez-Cibrián N., Bachiller M., Alserawan L., Ortiz-Maldonado V., Guedan S., Delgado J.. The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies. British Journal of Haematology. May 2024. DOI: 10.1111/bjh.19348.
Impacto: 5.1. Cuartil: Q1
Tam C.S., Opat S., D'Sa S., Jurczak W., Lee H.P., Cull G., Owen R.G., Marlton P., Wahlin B.E., García-San R., McCarthy H., Mulligan S., Tedeschi A., Castillo J.J., Czyz J., De Larrea C.F., Belada D., Libby E., Matous J., Motta M., Siddiqi T., Tani M., Trnený M., Minnema M.C., Buske C., Leblond V., Treon S.P., Trotman J., Wu B., Yu Y., Shen Z., Chan W.Y., Schneider J., Allewelt H., Cohen A., Dimopoulos M.A.. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia. Blood Advances. 9 April 2024. DOI: 10.1182/bloodadvances.2023010906.
Impacto: 7.4. Cuartil: Q1
Playa-Albinyana H., Arenas F., Royo R., Giró A., López-Oreja I., Aymerich M., López-Guerra M., Frigola G., Beà S., Delgado J., Garcia-Roves P.M., Campo E., Nadeu F., Colomer D.. Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation. Leukemia. March 2024. DOI: 10.1038/s41375-023-02095-5.
Impacto: 12.8. Cuartil: Q1
(1er decil)
Garcia-Pouton N., Ortiz-Maldonado V., Peyrony O., Chumbita M., Aiello T.F., Monzo-Gallo P., Lopera C., Puerta-Alcalde P., Magnano L., Martinez-Cibrian N., Pitart C., Juan M., Delgado J., Fernandez De Larrea C., Soriano Á., Urbano-Ispizua Á., Garcia-Vidal C.. Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy. European Journal of Haematology. March 2024. DOI: 10.1111/ejh.14122.
Impacto: 2.3. Cuartil: Q2
Martínez-Cibrián N., Ortiz-Maldonado V., Español-Rego M., Blázquez A., Cid J., Lozano M., Magnano L., Giné E., Correa J.G., Mozas P., Rodríguez-Lobato L.G., Rivero A., Montoro-Lorite M., Ayora P., Navarro S., Alserawan L., González-Navarro E.A., Castellà M., Sánchez-Castañón M., Cabezón R., Benítez-Ribas D., Setoaín X., Rodríguez S., Brillembourg H., Varea S., Olesti E., Guillén E., Sáez-Peñataro J., de Larrea C.F., López-Guillermo A., Pascal M., Urbano-Ispizua Á., Juan M., Delgado J.. The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology. February 2024. DOI: 10.1111/bjh.19170.
Impacto: 5.1. Cuartil: Q1
Rossig C., Pearson A.D., Vassal G., Scobie N., Bird N., Blanc P., Vormoor H.J., Calkoen F.G., Locatelli F., del Bufalo F., Rives S., Jacoby E., Balduzzi A., Bourquin J.P., Baruchel A.. Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed. Journal of Clinical Oncology. 20 January 2024. DOI: 10.1200/JCO.23.01314.
Impacto: 42.1. Cuartil: Q1
(1er decil)
Molinos-Quintana Á., Martínez-Cibrian N., Alonso-Saladrigues A., Galán-Gómez V., Bailén R., Buendía-López S., Fuentes-Socorro C., Kwon M., González-Vincent M., Pérez de Soto C., González-Martínez B., Rives S., Pérez-Hurtado J.M., Ortiz-Maldonado V., Pérez-Simón J.A.. Successful allogeneic CD34<sup>+</sup> hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC). Bone Marrow Transplantation. 2024. DOI: 10.1038/s41409-024-02473-2.
Impacto: 4.5. Cuartil: Q1
Mozas P., Casanueva-Eliceiry S., Rivero A., Serna Á., Simó M., Rodríguez S., Rivas-Delgado A., Nadeu F., Correa J.G., Piñeyroa J.A., Pérez-Valencia A.I., Guinetti-Ortiz K., Gómez-Hernando M., Giné E., Delgado J., Villamor N., Campo E., Magnano L., Abrisqueta P., Setoain X., López-Guillermo A.. A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma. Hematological Oncology. January 2024. DOI: 10.1002/hon.3235.
Impacto: 3.3. Cuartil: Q2
Molinos-Quintana Á., Alonso-Saladrigues A., Herrero B., Caballero-Velázquez T., Galán-Gómez V., Panesso M., Torrebadell M., Delgado-Serrano J., Pérez de Soto C., Faura A., González-Martínez B., Castillo-Robleda A., Diaz-de-Heredia C., Pérez-Martínez A., Pérez-Hurtado J.M., Rives S., Pérez-Simón J.A.. Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring (Front. Immunol., (2024), 14, 1280580, 10.3389/fimmu.2023.1280580). Frontiers in Immunology. 2024. DOI: 10.3389/fimmu.2024.1373852.
Impacto: 5.7. Cuartil: Q1
Gallego-Valle J., Pérez-Fernández V.A., Rosales-Magallares J., Gil-Manso S., Castellá M., Gonzalez-Navarro E.A., Correa-Rocha R., Juan M., Pion M.. High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy. Frontiers in Immunology. 2024. DOI: 10.3389/fimmu.2024.1448752.
Impacto: 5.7. Cuartil: Q1
Syrykh C., Pons-Brun B., Russiñol N., Playa-Albinyana H., Baumann T., Duran-Ferrer M., Kulis M., Carbó-Meix A., Mozas P., Alcoceba M., González M., Navarro-Bailón A., Colado E., Payer Á.R., Aymerich M., Terol M.J., Lu J., Knisbacher B.A., Hahn C.K., Ruiz-Gaspà S., Enjuanes A., Wu C.J., Getz G., Zenz T., López-Guillermo A., Martín-Subero J.I., Colomer D., Delgado J., Campo E., Nadeu F.. IGLV3-21<sup>R110</sup> mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia. Blood Advances. 12 December 2023. DOI: 10.1182/bloodadvances.2023010132.
Impacto: 7.4. Cuartil: Q1
Rives S.. Central nervous system therapy in acute lymphoblastic leukemia: no more, no less. Haematologica. December 2023. DOI: 10.3324/haematol.2023.283275.
Impacto: 8.2. Cuartil: Q1
Fernández-Garnacho E.M., Nadeu F., Martín S., Mozas P., Rivero A., Delgado J., Giné E., López-Guillermo A., Duran-Ferrer M., Salaverria I., López C., Beà S., Demajo S., Jares P., Puente X.S., Martín-Subero J.I., Campo E., Hernández L.. MALAT1 expression is associated with aggressive behavior in indolent B-cell neoplasms. Scientific Reports. December 2023. DOI: 10.1038/s41598-023-44174-8.
Impacto: 3.8. Cuartil: Q1
Visentin A., Chatzikonstantinou T., Scarfò L., Kapetanakis A., Demosthenous C., Karakatsoulis G., Minga E., Chamou D., Allsup D., Cabrero A.A., Andres M., Antic D., Baile M., Baliakas P., Besikli-Dimou S., Bron D., Chatzileontiadou S., Cordoba R., Correa J.G., Cuéllar-García C., De Paoli L., De Paolis M.R., Delgado J., Dimou M., Donaldson D., Catherwood M., Doubek M., Efstathopoulou M., Eichhorst B., Elashwah S., Enrico A., Espinet B., Farina L., Ferrari A., Foglietta M., Frederiksen H., Fürstenau M., García-Marco J.A., García-Serra R., Collado R., Gentile M., Gimeno E., Glenthøj A., da Silva M.G., Hakobyan Y.K., Herishanu Y., Hernández-Rivas J.Á., Herold T., Innocenti I., Itchaki G., Jaksic O., Janssens A., Kalashnikova О.B., Kalicińska E., Kater A.P., Kersting S., Labrador J., Lad D., Laurenti L., Levin M.D., Lista E., Lopez-Garcia A., Malerba L., Marasca R., Marchetti M., Marquet J., Mattsson M., Mauro F.R., Morawska M., Motta M., Munir T., Murru R., Niemann C.U., Rodrigues R.N., Olivieri J., Orsucci L., Papaioannou M., Pavlovsky M.A., Piskunova I., Popov V.M., Quaglia F.M., Quaresmini G., Qvist K., Rigolin G.M., Ruchlemer R., Šimkovič M., Špaček M., Sportoletti P., Stanca O., Tadmor T., Capasso A., Del Poeta G., Gutwein O., Karlsson L.K., Milosevic I., Mirás F., Reda G., Saghumyan G., Shrestha A., Te Raa D.. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. American Journal of Hematology. December 2023. DOI: 10.1002/ajh.27093.
Impacto: 10.1. Cuartil: Q1
(1er decil)
Dimopoulos M.A., Opat S., D'Sa S., Jurczak W., Lee H.P., Cull G., Owen R.G., Marlton P., Wahlin B.E., Garcia-Sanz R., McCarthy H., Mulligan S., Tedeschi A., Castillo J.J., Czyz J., Fernández De Larrea C., Belada D., Libby E., Matous J., Motta M., Siddiqi T., Tani M., Trnäný M., Minnema M.C., Buske C., Leblond V., Treon S.P., Trotman J., Chan W.Y., Schneider J., Allewelt H., Patel S., Cohen A., Tam C.S.. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis from the Randomized Phase III ASPEN Study. Journal of Clinical Oncology. 20 November 2023. DOI: 10.1200/JCO.22.02830.
Impacto: 42.1. Cuartil: Q1
(1er decil)
Rodríguez-Lobato L.G., Tovar N., de Daniel A., Fernández de Larrea C., Cibeira M.T., Jiménez-Segura R., Moreno D.F., Oliver-Caldés A., Bladé J., Rosiñol L.. Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution. Cancers. November 2023. DOI: 10.3390/cancers15215261.
Impacto: 4.5. Cuartil: Q1
Mozas P., López C., Grau M., Nadeu F., Clot G., Valle S., Kulis M., Navarro A., Ramis-Zaldivar J.E., González-Farré B., Rivas-Delgado A., Rivero A., Frigola G., Balagué O., Giné E., Delgado J., Villamor N., Matutes E., Magnano L., García-Sanz R., Huet S., Russell R.B., Campo E., López-Guillermo A., Beà S.. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors. Hematological Oncology. October 2023. DOI: 10.1002/hon.3132.
Impacto: 3.3. Cuartil: Q2
Rejeski K., Subklewe M., Aljurf M., Bachy E., Balduzzi A., Barba P., Bruno B., Benjamin R., Carrabba M.G., Chabannon C., Ciceri F., Corradini P., Delgado J., Di Blasi R., Greco R., Houot R., Iacoboni G., Jäger U., Kersten M.J., Mielke S., Nagler A., Onida F., Peric Z., Roddie C., Ruggeri A., Sánchez-Guijo F., Sánchez-Ortega I., Schneidawind D., Schubert M.L., Snowden J.A., Thieblemont C., Topp M., Zinzani P.L., Gribben J.G., Bonini C., Sureda A., Yakoub-Agha I.. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 7 September 2023. DOI: 10.1182/blood.2023020578.
Impacto: 21.0. Cuartil: Q1
(1er decil)
Alaggio R., Amador C., Anagnostopoulos I., Attygalle A.D., de Oliveira Araujo I.B., Berti E., Bhagat G., Borges A.M., Boyer D., Calaminici M., Chadburn A., Chan J.K.C., Cheuk W., Chng W.J., Choi J.K., Chuang S.S., Coupland S.E., Czader M., Dave S.S., de Jong D., Di Napoli A., Du M.Q., Elenitoba-Johnson K.S., Ferry J., Geyer J., Gratzinger D., Guitart J., Gujral S., Harris M., Harrison C.J., Hartmann S., Hochhaus A., Jansen P.M., Karube K., Kempf W., Khoury J., Kimura H., Klapper W., Kovach A.E., Kumar S., Lazar A.J., Lazzi S., Leoncini L., Leung N., Leventaki V., Li X.Q., Lim M.S., Liu W.P., Louissaint A., Marcogliese A., Medeiros L.J., Michal M., Miranda R.N., Mitteldorf C., Montes-Moreno S., Morice W., Nardi V., Naresh K.N., Natkunam Y., Ng S.B., Oschlies I., Ott G., Parrens M., Pulitzer M., Rajkumar S.V., Rawstron A.C., Rech K., Rosenwald A., Said J., Sarkozy C., Sayed S., Saygin C., Schuh A., Sewell W., Siebert R., Sohani A.R., Suzuki R., Tooze R., Traverse-Glehen A., Vega F., Vergier B., Wechalekar A.D., Wood B., Xerri L., Xiao W., Akinola N.O., Akkari Y., Allende L.M., Aozasa K., Arcaini L., Ardeshna K.M., Asano N., Attarbaschi A., Bacon C.M., Barrans S.L., Batchelor T., Battistella M., Baughn L.B., Behdad A., Berentsen S.. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2). Leukemia. September 2023. DOI: 10.1038/s41375-023-01962-5.
Impacto: 12.8. Cuartil: Q1
(1er decil)
Velasco P., Bautista F., Rubio A., Aguilar Y., Rives S., Dapena J.L., Pérez A., Ramirez M., Saiz-Ladera C., Izquierdo E., Escudero A., Camós M., Vega-García N., Ortega M., Hidalgo-Gómez G., Palacio C., Menéndez P., Bueno C., Montero J., Romecín P.A., Zazo S., Alvarez F., Parras J., Ortega-Sabater C., Chulián S., Rosa M., Cirillo D., García E., García J., Manzano-Muñoz A., Minguela A., Fuster J.L.. The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP). Frontiers in Pediatrics. 22 August 2023. DOI: 10.3389/fped.2023.1269560.
Impacto: 2.1. Cuartil: Q2
Moreno D.F., Fernández de Larrea C.. Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America. August 2023. DOI: 10.1016/j.hoc.2023.04.002.
Impacto: 2.5. Cuartil: Q2
Oliver-Caldés A., González-Calle V., Cabañas V., Español-Rego M., Rodríguez-Otero P., Reguera J.L., López-Corral L., Martin-Antonio B., Zabaleta A., Inogés S., Varea S., Rosiñol L., López-Díaz de Cerio A., Tovar N., Jiménez R., López-Parra M., Rodríguez-Lobato L.G., Sánchez-Salinas A., Olesti E., Calvo-Orteu M., Delgado J., Pérez-Simón J.A., Paiva B., Prósper F., Sáez-Peñataro J., Juan M., Moraleda J.M., Mateos M.V., Pascal M., Urbano-Ispizua A., Fernández de Larrea C.. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. The Lancet Oncology. August 2023. DOI: 10.1016/S1470-2045(23)00222-X.
Impacto: 41.6. Cuartil: Q1
(1er decil)
Tesileanu C.M.S., Michaleas S., Gonzalo Ruiz R., Mariz S., Fabriek B.O., Van Hennik P.B., Dedorath J., Dekic B., Unkrig C., Brandt A., Koenig J., Enzmann H., Delgado J., Pignatti F.. The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors. Oncologist. July 2023. DOI: 10.1093/oncolo/oyad119.
Impacto: 4.8. Cuartil: Q1
Gazeau N., Liang E.C., Wu Q.“., Voutsinas J.M., Barba P., Iacoboni G., Kwon M., Ortega J.L.R., López-Corral L., Hernani R., Ortiz-Maldonado V., Martínez-Cibrian N., Martinez A.P., Maziarz R.T., Williamson S., Nemecek E.R., Shadman M., Cowan A.J., Green D.J., Kimble E., Hirayama A.V., Maloney D.G., Turtle C.J., Gauthier J.. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. July 2023. DOI: 10.1016/j.jtct.2023.04.001.
Impacto: 3.6. Cuartil: Q1
Esperanza-Cebollada E., Gómez-González S., Perez-Jaume S., Vega-García N., Vicente-Garcés C., Richarte-Franqués M., Rives S., Català A., Torrebadell M., Camós M.. A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia. British Journal of Haematology. July 2023. DOI: 10.1111/bjh.18746.
Impacto: 5.1. Cuartil: Q1
Sánchez-Guijo F., Avendaño-Solá C., Badimón L., Bueren J.A., Canals J.M., Delgadillo J., Delgado J., Eguizábal C., Fernández-Santos M.E., García-Olmo D., González-Aseguinolaza G., Juan M., Martín F., Mata R., Montserrat N., Pérez-Martínez A., Pérez-Simón J.A., Prósper F., Urbano-Ispizua Á., Zapata A.G., Sureda A., Moraleda J.M.. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV). Bone Marrow Transplantation. June 2023. DOI: 10.1038/s41409-023-01962-0.
Impacto: 4.5. Cuartil: Q1
Aiello T.F., Puerta-Alcalde P., Chumbita M., Lopera C., Monzó P., Cortes A., Fernández-Avilés F., Suárez-Lledó M., Correa J., Ortiz-Maldonado V., Cuesta G., Martinez-Cibrian N., Esteve J., Marcos M.Á., Mensa J., Soriano A., Garcia-Vidal C.. Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals. Journal of Antimicrobial Chemotherapy. 1 June 2023. DOI: 10.1093/jac/dkad105.
Impacto: 3.9. Cuartil: Q1
Mussetti A., Bento L., Bastos-Oreiro M., Rius-Sansalvador B., Albo C., Bailen R., Barba P., Benzaquén A., Briones J., Caballero A.C., Campos A., Español I., Ferra C., López S.G., González Sierra P.A., Guerra L.M., Hernani R., Iacoboni G., Jiménez-Ubieto A., Kwon M., Corral L.L., López-Godino O., Munoz M.C.M., Martínez-Cibrián N., Gómez J.M., Pérez-Ortega L., Ortí G., Ortiz-Maldonado V., Pascual M.J., Perera M., Perez A., Reguera J.L., Sanchez J.M., Sanz J., Torrent A., Yáñez L., Varela R., Echechipia I.C., Caballero D., Sureda A.. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x). Bone Marrow Transplantation. June 2023. DOI: 10.1038/s41409-023-01967-9.
Impacto: 4.5. Cuartil: Q1
Mussetti A., Bento L., Bastos-Oreiro M., Rius-Sansalvador B., Albo C., Bailen R., Barba P., Benzaquén A., Briones J., Caballero A.C., Campos A., Español I., Ferra C., López S.G., González Sierra P.A., Guerra L.M., Hernani R., Iacoboni G., Jiménez-Ubieto A., Kwon M., Corral L.L., López-Godino O., Munoz M.C.M., Martínez-Cibrián N., Gómez J.M., Pérez-Ortega L., Ortí G., Ortiz-Maldonado V., Pascual M.J., Perera M., Perez A., Reguera J.L., Sanchez J.M., Sanz J., Torrent A., Yáñez L., Varela R., Echechipia I.C., Caballero D., Sureda A.. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era. Bone Marrow Transplantation. June 2023. DOI: 10.1038/s41409-023-01949-x.
Impacto: 4.5. Cuartil: Q1
Moreno C., Ramos-Elbal E., Velasco P., Aguilar Y., Gonzáález Martínez B., Fuentes C., Molinos Á., Guerra-García P., Palomo P., Verdu J., Adán Pedroso R.M., Vagace J.M., López-Duarte M., Regueiro A., Tasso M., Dapena J.L., Salinas J.A., Navarro S., Bautista F., Lassaletta Á., Lendínez F., Rives S., Pascual A., Rodríguez A., Pérez-Hurtado J.M., Fernández J.M., Pérez-Martínez A., González-Vicent M., Díaz de Heredia C., Fuster J.L.. Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet). Frontiers in Pediatrics. 3 May 2023. DOI: 10.3389/fped.2023.1140637.
Impacto: 2.1. Cuartil: Q2
Moreno-Castaño A.B., Fernández S., Ventosa H., Palomo M., Martinez-Sanchez J., Ramos A., Ortiz-Maldonado V., Delgado J., Fernández De Larrea C., Urbano-Ispizua A., Penack O., Nicolás J.M., Téllez A., Escolar G., Carreras E., Fernández-Avilés F., Castro P., Diaz-Ricart M.. Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: Laboratory tools for an early and differential diagnosis. Journal for ImmunoTherapy of Cancer. 12 April 2023. DOI: 10.1136/jitc-2022-006365.
Impacto: 10.3. Cuartil: Q1
(1er decil)
Del Giudice I., Cappelli L.V., Delgado J., Niemann C.U., Andersen M.A., Rotbain E.H.C., Aarup K., Walewska R., Visentin A., Deodato M., Frustaci A.M., Cavalloni C., Gentile M., Yassin M.A., Lad D., Scarfò L., Flogegard M., Mattsson M., Raponi S., Ilari C., Starza I.D., Orlandi E.M., Tedeschi A., Trentin L., Semenzato G., Guarini A., Ghia P., Montserrat E., Foà R.. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature. British Journal of Haematology. April 2023. DOI: 10.1111/bjh.18696.
Impacto: 5.1. Cuartil: Q1
Español-Rego M., Fernández-Martos C., Elez E., Foguet C., Pedrosa L., Rodríguez N., Ruiz-Casado A., Pineda E., Cid J., Cabezón R., Oliveres H., Lozano M., Ginés A., García-Criado A., Ayuso J.R., Pagés M., Cuatrecasas M., Torres F., Thomson T., Cascante M., Benítez-Ribas D., Maurel J.. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study. Cancer Immunology, Immunotherapy. April 2023. DOI: 10.1007/s00262-022-03283-5.
Impacto: 4.6. Cuartil: Q1
Laetsch T.W., Maude S.L., Rives S., Hiramatsu H., Bittencourt H., Bader P., Baruchel A., Boyer M., De Moerloose B., Qayed M., Buechner J., Pulsipher M.A., Myers G.D., Stefanski H.E., Martin P.L., Nemecek E., Peters C., Yanik G., Khaw S.L., Davis K.L., Krueger J., Balduzzi A., Boissel N., Tiwari R., O'Donovan D., Grupp S.A.. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. Journal of Clinical Oncology. 20 March 2023. DOI: 10.1200/JCO.22.00642.
Impacto: 42.1. Cuartil: Q1
(1er decil)
Merlini G., Sarosiek S., Benevolo G., Cao X., Dimopoulos M., Garcia-Sanz R., Gatt M.E., Fernandez de Larrea C., San-Miguel J., Treon S.P., Minnema M.C.. Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis. Seminars in Hematology. March 2023. DOI: 10.1053/j.seminhematol.2023.03.002.
Impacto: 5.0. Cuartil: Q1
Piñeyroa J.A., Cid J., Vlagea A., Carbassé G., Henao P., Bailo N., Ortiz-Maldonado V., Martínez-Cibrian N., Español M., Delgado J., Urbano-Ispizua Á., Lozano M.. Evaluation of cell collection efficiency in non-mobilized adult donors for autologous chimeric antigen receptor T-cell manufacturing. Vox Sanguinis. March 2023. DOI: 10.1111/vox.13394.
Impacto: 1.8. Cuartil: Q3
Garcia-Sanz R., Varettoni M., Jiménez C., Ferrero S., Poulain S., San-Miguel J.F., Guerrera M.L., Drandi D., Bagratuni T., McMaster M., Roccaro A.M., Roos-Weil D., Leiba M., Li Y., Qiu L., Hou J., De Larrea C.F., Castillo J.J., Dimopoulos M., Owen R.G., Treon S.P., Hunter Z.R.. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia. Seminars in Hematology. March 2023. DOI: 10.1053/j.seminhematol.2023.03.007.
Impacto: 5.0. Cuartil: Q1
Mansouri L., Thorvaldsdottir B., Sutton L.A., Karakatsoulis G., Meggendorfer M., Parker H., Nadeu F., Brieghel C., Laidou S., Moia R., Rossi D., Catherwood M., Kotaskova J., Delgado J., Rodríguez-Vicente A.E., Benito R., Rigolin G.M., Bonfiglio S., Scarfo L., Mattsson M., Davis Z., Gogia A., Rani L., Baliakas P., Foroughi-Asl H., Jylhä C., Skaftason A., Rapado I., Miras F., Martinez-Lopez J., de la Serna J., Rivas J.M.H., Thornton P., Larráyoz M.J., Calasanz M.J., Fésüs V., Mátrai Z., Bödör C., Smedby K.E., Espinet B., Puiggros A., Gupta R., Bullinger L., Bosch F., Tazón-Vega B., Baran-Marszak F., Oscier D., Nguyen-Khac F., Zenz T., Terol M.J., Cuneo A., Hernández-Sánchez M., Pospisilova S., Mills K., Gaidano G., Niemann C.U., Campo E., Strefford J.C., Ghia P., Stamatopoulos K., Rosenquist R.. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y). Leukemia. February 2023. DOI: 10.1038/s41375-023-01813-3.
Impacto: 12.8. Cuartil: Q1
(1er decil)
Mansouri L., Thorvaldsdottir B., Sutton L.A., Karakatsoulis G., Meggendorfer M., Parker H., Nadeu F., Brieghel C., Laidou S., Moia R., Rossi D., Catherwood M., Kotaskova J., Delgado J., Rodríguez-Vicente A.E., Benito R., Rigolin G.M., Bonfiglio S., Scarfo L., Mattsson M., Davis Z., Gogia A., Rani L., Baliakas P., Foroughi-Asl H., Jylhä C., Skaftason A., Rapado I., Miras F., Martinez-Lopez J., de la Serna J., Rivas J.M.H., Thornton P., Larráyoz M.J., Calasanz M.J., Fésüs V., Mátrai Z., Bödör C., Smedby K.E., Espinet B., Puiggros A., Gupta R., Bullinger L., Bosch F., Tazón-Vega B., Baran-Marszak F., Oscier D., Nguyen-Khac F., Zenz T., Terol M.J., Cuneo A., Hernández-Sánchez M., Pospisilova S., Mills K., Gaidano G., Niemann C.U., Campo E., Strefford J.C., Ghia P., Stamatopoulos K., Rosenquist R.. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia. February 2023. DOI: 10.1038/s41375-022-01802-y.
Impacto: 12.8. Cuartil: Q1
(1er decil)
Ruiz-Llobet A., Gassiot S., Sarrate E., Zubicaray J., Rives S., Suleman W., Berrueco R.. Thrombin generation profile using ST-Genesia after PEG-asparaginase in pediatric patients with acute lymphoblastic leukemia. Thrombosis and Haemostasis. 2023. DOI: 10.1055/a-2316-4547.
Impacto: 5.0. Cuartil: Q1
Kwon M., Iacoboni G., Reguera J.L., López Corral L., Morales R.H., Ortiz-Maldonado V., Guerreiro M., Caballero A.C., Domínguez M.L.G., Pina J.M.S., Mussetti A., Sancho J.M., Bastos-Oreiro M., Catala E., Delgado J., Henriquez H.L., Sanz J., Calbacho M., Bailén R., Carpio C., Ribera J.M., Sureda A., Briones J., Hernandez-Boluda J.C., Cebrián N.M., Martin J.L.D., Martín A., Barba P.. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. January 2023. DOI: 10.3324/haematol.2022.280805.
Impacto: 8.2. Cuartil: Q1
Pérez-Amill L., Bataller À., Delgado J., Esteve J., Juan M., Klein-González N.. Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development. Frontiers in Immunology. 2023. DOI: 10.3389/fimmu.2023.1260470.
Impacto: 5.7. Cuartil: Q1
Molinos-Quintana Á., Alonso-Saladrigues A., Herrero B., Caballero-Velázquez T., Galán-Gómez V., Panesso M., Torrebadell M., Delgado-Serrano J., Pérez de Soto C., Faura A., González-Martínez B., Castillo-Robleda A., Diaz-de-Heredia C., Pérez-Martínez A., Pérez-Hurtado J.M., Rives S., Pérez-Simón J.A.. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Frontiers in Immunology. 2023. DOI: 10.3389/fimmu.2023.1280580.
Impacto: 5.7. Cuartil: Q1
Nogués-Castell J., Feu-Basilio S., Felguera García Ó., Fernández de Larrea C., Oliver-Caldés A., Balagué Ponz O., Fassi J.M.. Bilateral orbital plasmacytomas as first sign of extramedullary progression post CAR-T therapy: case report and literature review. Frontiers in Oncology. 2023. DOI: 10.3389/fonc.2023.1217714.
Impacto: 3.5. Cuartil: Q2
Bravo J., Baltasar Tello P., González Garcia E., Ríos Herranz E., Páyer A.R., Terol Castera M.J., Champ D., Medina Perez A., Gironella M., Fernández Zarzoso M., Forés R., Delgado J., Garcia-Marco J.A.. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study. Leukemia and Lymphoma. 2023. DOI: 10.1080/10428194.2023.2216327.
Impacto: 2.2. Cuartil: Q3
Caballero-Bellón M., Alonso-Saladrigues A., Bobillo-Perez S., Faura A., Arqués L., Rivera C., Català A., Dapena J.L., Rives S., Jordan I.. Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study. Frontiers in Immunology. 2023. DOI: 10.3389/fimmu.2023.1219289.
Impacto: 5.7. Cuartil: Q1
San-Miguel J., Dhakal B., Yong K., Spencer A., Anguille S., Mateos M.V., Fernández De Larrea C., Martínez-López J., Moreau P., Touzeau C., Leleu X., Avivi I., Cavo M., Ishida T., Kim S.J., Roeloffzen W., Van De Donk N.W.C.J., Dytfeld D., Sidana S., Costa L.J., Oriol A., Popat R., Khan A.M., Cohen Y.C., Ho P.J., Griffin J., Lendvai N., Lonardi C., Slaughter A., Schecter J.M., Jackson C.C., Connors K., Li K., Zudaire E., Chen D., Gilbert J., Yeh T.M., Nagle S., Florendo E., Pacaud L., Patel N., Harrison S.J., Einsele H.. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. New England Journal of Medicine. 2023. DOI: 10.1056/NEJMoa2303379.
Impacto: 96.2. Cuartil: Q1
(1er decil)
Vicente-Garcés C., Maynou J., Fernández G., Esperanza-Cebollada E., Torrebadell M., Català A., Rives S., Camós M., Vega-García N.. Fusion InPipe, an integrative pipeline for gene fusion detection from RNA-seq data in acute pediatric leukemia. Frontiers in Molecular Biosciences. 2023. DOI: 10.3389/fmolb.2023.1141310.
Impacto: 3.9. Cuartil: Q2
Moreno D.F., López-Guerra M., Paz S., Oliver-Caldés A., Mena M.P., Correa J.G., Battram A.M., Osuna M., Rivas-Delgado A., Rodríguez-Lobato L.G., Cardús O., Tovar N., Cibeira M.T., Jiménez-Segura R., Bladé J., Rosiñol L., Colomer D., Fernández de Larrea C.. Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia. British Journal of Haematology. January 2023. DOI: 10.1111/bjh.18502.
Impacto: 5.1. Cuartil: Q1
Lickefett B., Chu L., Ortiz-Maldonado V., Warmuth L., Barba P., Doglio M., Henderson D., Hudecek M., Kremer A., Markman J., Nauerth M., Negre H., Sanges C., Staber P.B., Tanzi R., Delgado J., Busch D.H., Kuball J., Luu M., Jäger U.. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Frontiers in Immunology. 2023. DOI: 10.3389/fimmu.2023.1303935.
Impacto: 5.7. Cuartil: Q1
Wondergem M.J., Almeida A., Brolin J., Fernandez De Larrea C., Van Havre N., Hemker B.T., Hollegien W., Navarro J.T., Prahladan M., Rovó A., Birgegård G.. The Progress Test of the European Hematology Association: A New Tool for Continuous Learning. HemaSphere. 30 December 2022. DOI: 10.1097/HS9.0000000000000815.
Impacto: 6.6. Cuartil: Q1
Royo R., Magnano L., Delgado J., Ruiz-Gil S., Gelpí J.L., Heyn H., Taylor M.A., Stankovic T., Puente X.S., Nadeu F., Campo E.. Correction: ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution (Blood Cancer Journal, (2022), 12, 6, (90), 10.1038/s41408-022-00686-6). Blood Cancer Journal. December 2022. DOI: 10.1038/s41408-022-00762-x.
Impacto: 12.8. Cuartil: Q1
(1er decil)
Oliver-Caldes A., Jiménez R., Español-Rego M.. Erratum: First report of CART treatment in AL Amyloidosis and relapsed/refractory multiple myeloma (J Immunother Cancer (2021) 9 (e003783) DOI: 10.1136/jitc-2021-003783). Journal for ImmunoTherapy of Cancer. 3 November 2022. DOI: 10.1136/jitc-2021-003783corr1.
Knisbacher B.A., Lin Z., Hahn C.K., Nadeu F., Duran-Ferrer M., Stevenson K.E., Tausch E., Delgado J., Barbera-Mourelle A., Taylor-Weiner A., Bousquets-Muñoz P., Diaz-Navarro A., Dunford A., Anand S., Kretzmer H., Gutierrez-Abril J., López-Tamargo S., Fernandes S.M., Sun C., Sivina M., Rassenti L.Z., Schneider C., Li S., Parida L., Meissner A., Aguet F., Burger J.A., Wiestner A., Kipps T.J., Brown J.R., Hallek M., Stewart C., Neuberg D.S., Martín-Subero J.I., Puente X.S., Stilgenbauer S., Wu C.J., Campo E., Getz G.. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nature Genetics. November 2022. DOI: 10.1038/s41588-022-01140-w.
Impacto: 30.8. Cuartil: Q1
(1er decil)
Maldonado-Pérez N., Tristán-Manzano M., Justicia-Lirio P., Martínez-Planes E., Muñoz P., Pavlovic K., Cortijo-Gutiérrez M., Blanco-Benítez C., Castella M., Juan M., Wenes M., Romero P., Molina-Estévez F.J., Marañón C., Herrera C., Benabdellah K., Martin F.. Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma. Frontiers in Immunology. 6 October 2022. DOI: 10.3389/fimmu.2022.1011858.
Impacto: 7.3. Cuartil: Q1
Ghorashian S., Jacoby E., De Moerloose B., Rives S., Bonney D., Shenton G., Bader P., Bodmer N., Quintana A.M., Herrero B., Algeri M., Locatelli F., Vettenranta K., Gonzalez B., Attarbaschi A., Harris S., Bourquin J.P., Baruchel A.. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. The Lancet Haematology. October 2022. DOI: 10.1016/S2352-3026(22)00225-3.
Impacto: 24.7. Cuartil: Q1
(1er decil)
Piñeyroa J.A., Magnano L., Rivero A., Rivas-Delgado A., Nadeu F., Correa J.G., Giné E., Villamor N., Filella X., Colomer D., López M., López-Oreja I., Costa D., Aymerich M., Beà S., López-Guillermo A., Campo E., Delgado J., Mozas P.. Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. Hematological Oncology. October 2022. DOI: 10.1002/hon.3027.
Impacto: 3.3. Cuartil: Q2